GNS vs. ONT, PRTC, SPI, CRW, UPR, AMS, MXCT, BMK, INDV, and HCM
Should you be buying Genus stock or one of its competitors? The main competitors of Genus include Oxford Nanopore Technologies (ONT), PureTech Health (PRTC), Spire Healthcare Group (SPI), Craneware (CRW), Uniphar (UPR), Advanced Medical Solutions Group (AMS), MaxCyte (MXCT), Benchmark (BMK), Indivior (INDV), and HUTCHMED (HCM). These companies are all part of the "medical" sector.
Genus (LON:GNS) and Oxford Nanopore Technologies (LON:ONT) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, valuation, dividends, profitability, institutional ownership, community ranking, media sentiment, earnings and analyst recommendations.
In the previous week, Oxford Nanopore Technologies had 2 more articles in the media than Genus. MarketBeat recorded 3 mentions for Oxford Nanopore Technologies and 1 mentions for Genus. Genus' average media sentiment score of 0.63 beat Oxford Nanopore Technologies' score of 0.20 indicating that Genus is being referred to more favorably in the media.
Genus has a net margin of 4.96% compared to Oxford Nanopore Technologies' net margin of -91.06%. Genus' return on equity of 5.27% beat Oxford Nanopore Technologies' return on equity.
Genus received 323 more outperform votes than Oxford Nanopore Technologies when rated by MarketBeat users. However, 100.00% of users gave Oxford Nanopore Technologies an outperform vote while only 70.56% of users gave Genus an outperform vote.
Genus has higher revenue and earnings than Oxford Nanopore Technologies. Oxford Nanopore Technologies is trading at a lower price-to-earnings ratio than Genus, indicating that it is currently the more affordable of the two stocks.
Genus presently has a consensus price target of GBX 4,500, indicating a potential upside of 157.14%. Oxford Nanopore Technologies has a consensus price target of GBX 303.75, indicating a potential upside of 200.66%. Given Oxford Nanopore Technologies' higher probable upside, analysts clearly believe Oxford Nanopore Technologies is more favorable than Genus.
78.2% of Genus shares are owned by institutional investors. Comparatively, 38.4% of Oxford Nanopore Technologies shares are owned by institutional investors. 0.7% of Genus shares are owned by insiders. Comparatively, 30.1% of Oxford Nanopore Technologies shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Genus has a beta of 0.31, suggesting that its share price is 69% less volatile than the S&P 500. Comparatively, Oxford Nanopore Technologies has a beta of 0.59, suggesting that its share price is 41% less volatile than the S&P 500.
Summary
Genus beats Oxford Nanopore Technologies on 10 of the 17 factors compared between the two stocks.
Get Genus News Delivered to You Automatically
Sign up to receive the latest news and ratings for GNS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GNS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
